Andrew L Laccetti MDHematology/Oncology Fellow, University of Texas MD Anderson Cancer Center, Houston, TX
Andrew Laccetti M.D. is currently a third-year hematology/oncology fellow at the University of Texas MD Anderson Cancer Center. Dr. Laccetti graduated summa cum laude from Union College in Schenectady, NY, where, as a member of the Leadership in Medicine Program, he earned bachelor’s degrees in both Chemistry and Music as well as a master’s degree in Clinical Leadership. Dr. Laccetti pursued his medical education at Albany Medical College and completed an internal medicine residency at UT Southwestern where he also served as chief medical resident.
While at UT Southwestern, Dr. Laccetti cultivated an interest in outcomes research, with a specific focus on optimization of clinical trial enrollment and design. He concluded that up to 18% of target accrual is unnecessarily disqualified from lung cancer trials on the basis of prior cancer history despite exhibiting non-inferior survival. This work lead to first author publications in high impact journals including the Journal of the National Cancer Institute as well as merit awards from the ECOG-ACRIN Young Investigator Symposium and the Prime Oncology Young Investigators Forum in Non-Small Cell Lung Cancer. Dr. Laccetti was also the first to report on rapidly increasing utilization of electronic health portals by oncology patients and clinic staff highlighting a critical need to examine impact on clinical resources and patient safety.
Expanding upon his foundation in clinical trial design and technology, Dr. Laccetti’s current research aims to develop a multimodal, remote monitoring platform for prostate cancer patients, utilizing Fitbit, smart phone-based symptom surveys and automated real-time data synthesis. Through development and application of this system, he hopes to enhance clinical trial toxicity monitoring, improve patient safety and, most importantly, better inform biologically driven treatments. Upon graduation from fellowship this year, Dr. Laccetti plans to continue his career as an academic medical oncologists with a focus on genitourinary malignancies.